The aim of the research was to investigate prognostic factors in patients with resected colorectal liver metastases (CLMs) after biological and chemotherapy, which made initially unresectable disease suitable for resection. Sixty-six patients with resected CLMs, operated after induction bio-chemotherapy with bevacizumab + FOLFOX4, treated at the Cl...

By Miljana Džunić, Ivan Petković, Ana Cvetanović, Ivica Pejčić, Svetislav Vrbić, Saša Dinić

...

By Ivan Petković, Aleksandar Popović, Miljana Džunić, Ivica Pejčić

Abstract The aim of the paper was to determine the efficacy, toxicity and progression free survival with anti-PD-1 immunotherapy pembrolizumab in BRAF wild type metastatic melanoma patients with good performance status (ECOG PS 0-1). From February 2017 to April 2018, 17 patients with BRAF mutant wild type metastatic melanoma were enrolled in th...

By Ivica Pejčić, Ivan Petković, Ana Cvetanović, Irena Conić

SummaryIn recent years, results obtained from different studies with large cohorts have revealed a bond between the presence of extensive lymphocytic infiltration and favourable prognostic associations in the early-stage of breast cancer (BC) and high response rates to neoadjuvant chemotherapy. Examiners used tumors from large cohorts of patients w...

By Ana Cvetanović, Slađana Filipović, Nikola Živković, Miloš Kostić, Svetislav Vrbić, Ivica Pejčić

Abstract The application of anthracycline and trastuzumab in adjuvant breast cancer treatment approach has significantly improved the survival of patients, but also carries the risk of cardiotoxicity that is manifested by reducing the ejection fraction of the heart. The aim of the study was to investigate the effect of cumulative anthracy...

By Ivana Krstić, Marina Deljanin Ilić, Svetislav Vrbić, Ivica Pejčić

SUMMARY By introduction of all-trans retinoic acid (ATRA) in de novo acute promyelocytic leukemia (APL) an revolution in therapy of this disease has been made. The rate of molecular complete remissions (CR) have been doubled compared to conventional chemotherapy with anthracyclines ranging from 90% to 95%. Consolidation therapy is required in ...

By Ivan Petković, Ivica Pejčić, Svetislav Vrbić

Summary Metastatic carcinomas of unknown primary origin (cancer of unknown primary-CUP) represent 3-5% of all cancers. This term includes all patients presented with metastatic disease in whom the primary site could not have been identified. Despite the use of modern and comprehensive diagnostic techniques and procedures, there is no improvement in...

By Ivica Pejčić, Svetislav Vrbić, Mirjana Todorović, Ivan Petković, Mirjana Balić, Ana Stanković

Summary Bone marrow involvement is rare in patients with Hodgkin lymphoma (HL). Its incidence varies with respect to risk factors from 4% to 14%. Low risk patients do not need trephine biopsy according to some research. In the era of positron emission tomography/computed tomography (PET/CT) staging prior to therapy, the role of trephine biopsy...

By Ivan Petković, Miljan Krstić, Slavica Stojnev, Ivica Pejčić, Svetislav Vrbić

SUMMARY Burkitt lymphoma (BL) is a disease of predominantly young population, while in the elderly it occurs as a rare neoplasm. Elderly patients (age >60 years) represent a significant problem because of the inability to apply effective aggressive chemiotherapy in these cases. The risk of induction death is very high and unacceptible. Main...

By Ivan Petković, Dragan Mihailović, Miljan Krstić, Ivica Pejčić, Svetislav Vrbić, Mirjana Balić